Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Pricing likely would be favorable, given the lack of alternative treatments. See disclosure here. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Events - Ocugen These options will be cheaper than owning the stock itself. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Ocugen to Present at the 2018 BIO International Convention | Ocugen, Inc. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Not an offer or recommendation by Stocktwits. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. If they have solid financials, but their trials continually fail, they will likely not succeed. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. The average Ocugen stock price for the last 52 weeks is 2.10. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Its certainly possible. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. The Motley Fool recommends Moderna Inc. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Theres an opportunity here. Keith Speights has no position in any of the stocks mentioned. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Keith Speights for When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Invest better with The Motley Fool. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. You canfollow Will on Twitterat @HealyWriting. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. Why Ocugen Stock Is Crashing Today | The Motley Fool - Nasdaq Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Accordingly, the analyst rates OCGN a Neutral (i.e. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. For priority reviews, the timeline for an approval decision is reduced to six months. In this case, shares rallied about four-fold in just a few days. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Part of the proceeds will be used to support its partnership with Bharat. The median estimate. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. To be sure, current cash isnt enough. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. OCGN | Ocugen Inc. Stock Price & News - WSJ Do Not Sell My Personal Information (CA Residents Only). After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. What should investors do now? Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Written by It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. There's still a chance that the vaccine could receive a green light in Canada. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. You never know when they will suddenly go on a squeeze. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. The statistics support having long-term exposure to this asset class. It has real products. Histogenics itself highlights the risks involved in small-cap biotech. As of this writing, Vince Martin has no positions in any securities mentioned. Like other life sciences companies involved in Covid-19 vaccine. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. From a near-term standpoint, there are two key risks. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Investors need to understand the risk profile here. At the time, Ocugen was left for dead. Copyright Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The odds of Ocugen stock winding up at zero are material. 1125 N. Charles St, Baltimore, MD 21201. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. *Stock Advisor returns as of June 7, 2021. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Investors should worry about companies with no revenue even under the best of circumstances. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. Theres even room for more lines. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Emergency Use . (See OCGN stock analysis on TipRanks). Literally, zero. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. This can prove to be a costly lesson to learn. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ocugen Stock Crashes: What Should Investors Do Now? Unfortunately for longs, OCGN is much closer to the worst of conditions. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The equity has experienced a continual decline for years. While anything is possible, I would not anticipate a miracle here. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Create your Watchlist to save your favorite quotes on Nasdaq.com. However, even from this limited vantage point, OCGN appears destined to fail. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. That said, for investors who understand the potential downside, there is an intriguing story here. Ill be sticking to the stocks that are actually working. All rights reserved. Ocugen Inc. is a clinical stage biopharmaceutical company. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Start trading Options with Saxo today. Even before that point, the most promising candidates generally can find funding. In that list, you can even include penny-stock trader. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The content is intended to be used for informational purposes only. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Copyright 2023 InvestorPlace Media, LLC. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. All rights reserved. Ocugen: Peripheral Scandals Taint This Expired COVID-19 'Me-Too' Longshot Type a symbol or company name. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. How long might it take for Ocugen to win full FDA approval for Covaxin? The FDA's decision not to issue EUA really wasn't all that surprising, though. But realizing value in practice usually is a difficult endeavor. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Still, Ocugens balance sheet isnt as dire as its share price might suggest. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. quotes delayed at least 15 minutes, all others at least 20 minutes. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Please check your download folder. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Objective investors could have clearly seen then that there actually were significant reasons to be concerned. Thats the thing with these low-priced penny stocks. Learn More. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. Maybe OCGN stock will be one of them again. Do not expect a recovery in Ocugen stock. That doesnt mean success is guaranteed. Sign up below to get this incredible offer! Typically, I care little about financials with biotechs. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. 7 Travel Stocks to Buy Banking On Pent-Up Demand. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Type a symbol or company name. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. 2023 InvestorPlace Media, LLC. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Our 3 Top Picks. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. Keith Speights owns shares of Pfizer. There Are So Many Stocks to Buy Ocugen Isn't One of Them Ocugen - Stock Price History | OCGN | MacroTrends Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. This decision. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. OCGN - Ocugen Inc Forecast - CNNMoney.com - CNN Business Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Keith Speights for The $25 million private placement executed before the merger brought in much-needed cash. The Motley Fool has no position in any of the stocks mentioned. Ocugen Inc. Announces Closing of $100 Million Registered On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. If OCU300 is approved, theres a reasonably large market. Do Not Sell My Personal Information (CA Residents Only). In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Cost basis and return based on previous market day close. Instead, this appears destined to join the long list of failed biotech startups. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Honestly, OCGN stock is unlikely to survive. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. The chances of anything more are small but the rewards could be huge. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. First, the balance sheet is in at least decent shape. Don't Get Greedy With Ocugen Stock, Says Analyst Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. It's hard to say for sure. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials.